Volume 26 | August 2019

Cover Story

Glucocorticoids (GCs) are extensively prescribed medicines due to their potent immuno­suppressive and anti-inflammatory properties. Prolonged high-dose GC use is associated with a range of metabolic side effects, including hyperphagia, obesity, and abnormal glucose homeostasis. The mechanisms driving these adverse metabolic effects remain unclear. A potential region involved in driving these GC-induced side effects is the hypothalamic arcuate nucleus, a region that is critical for the regulation of feeding and metabolism.

Wray et al. used a global transcriptomic approach to investigate the effects of GCs in the hypothalamus. This revealed a variety of genes involved in energy regulation, of which type-II iodothyronine deiodinase (Dio2) was selected as the most promising candidate for further study. A knockdown of Dio2 attenuated the GC-induced increase in Agrp; however, knockdown conferred no protection from the observed hyperphagia or weight gain. The range of both known and novel candidate genes indicates that multiple mechanisms may contribute to the metabolic abnormalities observed with GC treatment.

Full Text


All Articles

Austin L. Good, Matthew W. Haemmerle, Alexis U. Oguh, Nicolai M. Doliba, Doris A. Stoffers

Mattias Backman, Florian Flenkenthaler, Andreas Blutke, Maik Dahlhoff, Erik Ländström, Simone Renner, Julia Philippou-Massier, Stefan Krebs, Birgit...

Brandon L. Roberts, Baylin J. Bennett, Camdin M. Bennett, Julie M. Carroll, Louise S. Dalbøge, Colin Hall, Wafa Hassouneh, Kristy M. Heppner, Melissa...

Jonathan R. Wray, Alison Davies, Charlotte Sefton, Tiffany-Jayne Allen, Antony Adamson, Philip Chapman, Brian Y.H. Lam, Giles S.H. Yeo, Anthony P....

Jaap Keijer, Min Li, John R. Speakman

Alexander W. Fischer, Barbara Cannon, Jan Nedergaard